Edwards Lifesciences Corporation (EW)

NYSE: EW · USD

$91.5

+0.68 (+0.8%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-10-02

Our latest published analysis: EW rated Sell

Edwards Lifesciences Corporation's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$62.3 / share

Potential value

$79.8 / share

Upside to FV

-27.3%

from $91.5

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$49.3B
Revenue (ttm)	6.5B
Net income (ttm)	1B
EPS (ttm)	$1.72
Shares out	576.4M
P/E (trailing)	53.2x
P/E (forward)	25.6x
Volume	1,655,953
Beta	0.86

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 6.5B
Net income (ttm): 1B
EPS (ttm): $1.72
P/E (trailing): 53.2x
P/E (forward): 25.6x
Market cap: $49.3B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$5.23B	$4.46B	$5.01B	$5.44B	$6.07B	+3.8%
Gross profit	$3.98B	$3.74B	$4.03B	$4.32B	$4.73B	+4.4%
Operating income	$1.69B	$1.50B	$1.31B	$1.38B	$1.26B	-7.0%
Net income	$1.50B	$1.52B	$1.40B	$4.17B	$1.07B	-8.1%
EPS (diluted)	$2.38	$2.44	$2.30	$6.97	$1.83	-6.4%
EBITDA	$1.89B	$1.96B	$1.53B	$1.72B	$1.43B	-6.7%
R&D	$903.1M	$843.6M	$962.9M	$1.05B	$1.08B	+4.6%
SG&A	$1.49B	$1.36B	$1.58B	$1.79B	$2.09B	+8.7%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base55%

Price target

$62.28

-27.3% from spot

Edwards maintains durable leadership in transcatheter heart valve replacement, supported by specialized clinician workflows and expanding center capacity under finalized NCD guidelines,. Revenue grows in line with consensus projections across FY2026 and FY2027 before fading toward terminal rates by FY2030. Operating margins expand from FY2026 through FY2030, supported by premium gross margins. Reinvestment moderates relative to NOPAT as capital expenditures scale down relative to revenue from FY2025 levels.

Revenue growth aligns with consensus expectations across FY2026 and FY2027 before fading toward mature rates by FY2030
Operating margins expand steadily from FY2026 through FY2030
Terminal price-to-earnings multiple compresses relative to the valuation date forward multiple
Reinvestment rate moderates relative to NOPAT as capital expenditures scale down

Bull20%

Price target

$79.82

-6.9% from spot

Accelerated implementation of finalized National Coverage Determination (NCD) policies opens substantial hospital cath lab capacity and center access, reigniting US TAVR procedural growth while early-stage asymptomatic indication expansions broaden the eligible patient population. Emerging transcatheter mitral and tricuspid therapies scale rapidly, lifting consolidated gross margin and operating margin. Normalizing capex intensity relative to revenue expands annual cash flows, driving accelerated share repurchases and compound earnings expansion.

Consolidated revenue growth accelerates above baseline guidance
Operating margins expand via SG&A leverage
Capex intensity normalizes toward maintenance levels of revenue
EVOQUE tricuspid adoption scales rapidly across structural heart centers

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($62.28). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	2.0%	2.5%	3.0%	3.5%
7.9%	$64.3	$66.0	$68.1	$70.7	$73.8
8.4%	$61.6	$63.1	$64.8	$66.9	$69.4
8.9%	$59.3	$60.6	$62.3	$63.7	$65.7
9.4%	$57.3	$58.3	$59.5	$60.9	$62.6
9.9%	$55.4	$56.3	$57.4	$58.5	$59.9

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E25.6

P25 n/aP50 n/aP75 n/a

Trailing P/E50.7

P25 n/aP50 n/aP75 n/a

ROE9.2

P25 n/aP50 n/aP75 n/a

ROIC17.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EW indicators

Market & fundamental data

Available fields

277

Groups with data

Currency

USD

Showing 277 of 277 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001099800
Company name	Edwards Lifesciences Corporation
Country	United States
Country code	US
CUSIP number	28176E108
Earnings date	2026-11-04
Earnings time	amc
Employees	16,000
Employees change	200
Employees growth	1.27%
Enterprise value	$49.2B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1958
In index	SP500
Industry	Medical Devices
IPO date	2000-03-27
Is primary listing	Yes
Is SPAC	No
ISIN number	US28176E1082
Last 10-K release date	2026-02-25
Last earnings date	2026-07-23
Last refreshed	2026-10-28
Last stock split date	2020-06-01
Last stock split type	Forward
Market cap	$52.7B
Market cap category	Large-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$91.50
Price currency	USD
Sector	Healthcare
SIC code	3842
Stock price date	2026-10-28
Symbol	EW
U.S. state	California
Website	https://www.edwards.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	32.56x
Average P/E ratio (10Y)	40.97x
Average P/E ratio (3Y)	29.63x
Average P/E ratio (5Y)	34.28x
Earnings yield	1.88%
EV/Earnings	49.17x
EV/EBIT	26.98x
EV/EBITDA	24.74x
EV/FCF	34.46x
EV/Sales	7.59x
FCF / EV yield	2.9%
FCF yield	2.71%
Forward EV/Sales	6.99x
Forward P/E	29.21x
Forward P/S	7.5x
Graham number	26.68849
Graham upside	-70.97%
Industry forward P/E	19.81x
Industry P/E	39.28x
Lynch fair value	$8.60
Lynch upside	-90.65%
P/(FCF - SBC) ratio	41.87x
P/(OCF - SBC) ratio	34.13x
P/B ratio	4.93x
P/E ratio	53.23x
P/FCF ratio	36.96x
P/OCF ratio	30.8x
P/S ratio	8.14x
PEG ratio	2.55x
Price / tangible book value	7.27x
Price/EBITDA ratio	26.54x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	28.12%
EBITDA margin	30.66%
Effective tax rate	30.97%
FCF margin	22.01%
Gross margin	77.84%
Operating margin	28.12%
Pretax margin	21.77%
Profit margin	15.43%
Profit per employee	$62,806
Profitable quarters	24
Profitable years	24
Revenue per employee	$407,019
ROA	8.37%
ROA (5Y)	10.1%
ROCE	14.82%
ROE	9.18%
ROE (5Y)	19.62%
ROIC	17.39%
ROIC (5Y)	24.51%
SBC / revenue	2.58%
Tax / revenue	6.74%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-75.5%
EPS growth (Q)	-25.39%
EPS growth (QoQ)	-36.15%
EPS growth 10Y	7.86%
EPS growth 3Y	-8.78%
EPS growth 5Y	-5.69%
EPS growth years	0
FCF growth	143.85%
FCF growth (Q)	142.84%
FCF growth 3Y	26.86%
FCF growth 5Y	6.41%
Gross profit growth	13.05%
Gross profit growth (Q)	13.54%
Gross profit growth 3Y	6.63%
Gross profit growth 5Y	6.38%
Net income growth	-75.77%
Net income growth (Q)	-27.4%
Net income growth (QoQ)	-36.46%
Net income growth 3Y	-10.24%
Net income growth 5Y	-7.23%
Net income growth years	0
OCF growth	116.42%
OCF growth (Q)	124.64%
OCF growth (QoQ)	1,388.36%
OCF growth 10Y	11.04%
OCF growth 3Y	22.3%
OCF growth 5Y	3.59%
Operating income growth	15.25%
Operating income growth (Q)	20.56%
Operating income growth 3Y	7.13%
Operating income growth 5Y	3.45%
Revenue growth	14.55%
Revenue growth (Q)	13.63%
Revenue growth (QoQ)	5.6%
Revenue growth 10Y	9.03%
Revenue growth 3Y	8.02%
Revenue growth 5Y	5.75%
Revenue growth quarters	9
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-286.7M
Depreciation and amortization	$165.5M
EBIT	$1.8B
EBITDA	$2B
EPS	$1.72
FCF per share	$2.49
Financing cash flow	$-1.2B
Free cash flow	$1.4B
Free cash flow minus SBC	$1.3B
Gross profit	$5.1B
Income taxes	$439M
Investing cash flow	$-912.1M
Net cash flow	$-380.3M
Net income	$1B
Operating cash flow minus SBC	$1.6B
Operating income	$1.8B
Revenue	$6.5B
Stock-based compensation	$168M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11.92
Book value per share	$18.41
Debt / EBITDA	0.35
Debt / equity	0.07
Debt / FCF	0.49
Goodwill	$2B
Interest coverage	89.77
Long-term assets	$7B
Long-term liabilities	$1.6B
Net cash (debt)	$3.6B
Net cash / market cap	6.75%
Net cash growth	6.31%
Net debt / EBITDA	-1.79
Net debt / equity	-0.33
Net debt / FCF	-2.5
Piotroski F-Score	4
Property, plant and equipment	$1.9B
Shareholders' equity	$10.7B
Tangible book value	$7.3B
Tangible book value per share	$12.63
Total assets	$13.9B
Total cash	$4.3B
Total debt	$704.4M
Total liabilities	$3.1B
WACC	8.91%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.48
Current assets	$6.8B
Current liabilities	$1.5B
Current ratio	4.52
Inventory turnover	1.27
Net working capital	$1.1B
Quick ratio	3.45
Working capital	$5.3B
Working capital turnover	1.24

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	1.64%
Dividend yield	0%
Shareholder yield	1.64%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	198.6%
10Y return CAGR	11.56%
10Y total return	198.6%
150-day SMA	$86.34
15Y price change	629.67%
15Y return CAGR	14.17%
15Y total return	629.69%
1D price change	0.75%
1M price change	6.35%
1M total return	6.35%
1W price change	3.94%
1W total return	3.94%
1Y price change	13.55%
1Y return CAGR	13.56%
1Y total return	13.55%
20-day SMA	$87.42
200-day SMA	$85.33
20Y price change	2,400.55%
20Y return CAGR	17.46%
20Y total return	2,400.55%
3M price change	10.51%
3M total return	10.51%
3Y price change	48.71%
3Y return CAGR	14.14%
3Y total return	48.71%
50-day SMA	$88.06
50-day SMA vs 200-day SMA	50over200
52-week high	$96.29
52-week high date	2026-07-07
52-week low	$74.66
52-week low date	2026-02-11
5Y price change	-20.94%
5Y return CAGR	-4.59%
5Y total return	-20.94%
6M price change	9.96%
6M total return	9.96%
All-time high	$131.73
All-time high date	2021-12-30
All-time low	$1.00
All-time low date	2000-11-01
Average true range (ATR)	$2.01
Average volume	3.3M
Beta (1Y)	0.59
Beta (2Y)	0.45
Beta (5Y)	0.86
Change from 52-week high	-4.97%
Change from 52-week low	22.56%
Change from all-time high	-30.33%
Change from all-time low	9,077%
Change from open	1.35%
Day's gap	-0.59%
Dollar volume	$151.5M
High price	$92.00
Low price	$90.25
Monthly RSI	57.51
Open price	$90.28
Position in 52-week range	71.43%
Premarket change	-0.01%
Premarket close	$90.82
Premarket price	$90.81
Premarket volume	142
Previous close	$90.82
Price vs 150-day SMA	6.29%
Price vs 20-day SMA	4.98%
Price vs 200-day SMA	7.55%
Price vs 50-day SMA	4.22%
Relative volume	0.5
RSI	63.58
Sharpe ratio	0.48
Sharpe ratio (3Y)	0.34
Sharpe ratio (5Y)	-0.09
Sortino ratio	0.94
Sortino ratio (3Y)	0.61
Sortino ratio (5Y)	0.04
Volume	1.7M
Weekly RSI	58.75
YTD price change	7.65%
YTD total return	7.65%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	574.5M
Float percentage	99.67%
Shares change (QoQ)	-0.53%
Shares change (YoY)	-1.64%
Shares held by insiders	0.22%
Shares held by institutions	92.84%
Shares outstanding	576.4M
Short % of float	1.66%
Short % of shares	1.65%
Short ratio	2.8 days

Deeper analysis on EW

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Scorecard

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this EW report

What is the latest published EW stock rating?

Edwards Lifesciences Corporation is shown with Sell in the latest published report, analyzed 2026-10-02. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full EW analysis?

The full latest published report, analyzed 2026-10-02, lives at /stocks/EW/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for EW?

The latest published report analyzed 2026-10-02 gives EW a fair value of USD 62 and a potential value of USD 80. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the EW page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-02). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellEW · Fair value $62.3-27.3%

Read full analysis →

Edwards Lifesciences Corporation (EW)

Our latest published analysis: EW rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · EW

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All EW indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on EW

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	1.5
Management	8.5
Balance Sheet	8.5
Profitability	5.5
Revenue Growth	6.0
Risk Assessment	8.0
Competitive Moat	9.0
Earnings Quality	6.0
Capital Efficiency	6.5